Collaborative Agreements (Tables)

3 Months Ended

Mar. 31, 2012

Takeda Agreement [Member]

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Schedule Of Activity Related To Collaboration

The following is a summary of activity related to the Takeda Agreement and the location in the consolidated statements of operations (in thousands):

		Three Months Ended
Activity	Classification within Consolidated Statements of  Operations	March 31, 2012		March 31, 2011
Amortization of up-front payments	Revenues under collaborative agreements	$	1,875	$	1,875
Cost-sharing payments due from Takeda for shared development expenses	Reduction of research and development expense	$	758	$	5,018

Lilly Collaboration [Member]

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Schedule Of Activity Related To Collaboration

The following is a summary of activity related to our collaboration with Lilly and the location in the consolidated statements of operations (in thousands):

	Classification within Consolidated Statements of Operations	Three Months Ended
Activity		March 31, 2012		March 31, 2011
Gross margin sharing	Collaborative profit sharing	$	—	$	59,851
Development expense cost-sharing payments received from Lilly for BYETTA and BYDUREON development expense	Reduction of research and development expense	$	—	$	17,346
Cost-sharing payments due from Lilly for shared sales force expenses, marketing expenses and other commercial or operational support	Reduction of selling, general and administrative expense	$	—	$	3,337